Skinny labelling in the Australian context: an overview
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be protected by several different patent claim formats, including method of...
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be...
Read More
IAM Patent 1000 2024
Spruson & Ferguson has once again been recognised in the 2024 IAM Patent 1000 rankings across the Asia-Pacific, with an outstanding result in multiple countries. We are delighted to announce the...
Spruson & Ferguson has once again been recognised in the 2024 IAM Patent 1000 rankings across the Asia-Pacific, with an outstanding...
Read More
Pharmaceutical patent term extension in Australia
This article was first published in the 2023 Pharmaceutical Patent Review. Patent term extensions (PTEs) can be of great commercial importance, and in recent years have become of particular interest...
This article was first published in the 2023 Pharmaceutical Patent Review. Patent term extensions (PTEs) can be of great commercial...
Read More
IP Australia releases 2024 Intellectual Property Report
IP Australia has released the twelfth edition of the Australian Intellectual Property Report 2024 (the Report) which presents key movements in IP statistics and explores the links between innovation,...
IP Australia has released the twelfth edition of the Australian Intellectual Property Report 2024 (the Report) which presents key...
Read More
The 2023 Pharmaceutical Patent Review
Welcome to Spruson & Ferguson’s wrap-up of the most notable developments in pharmaceutical patent law in Australia in 2023. The past year saw a number of important Federal Court...
Welcome to Spruson & Ferguson’s wrap-up of the most notable developments in pharmaceutical patent law in Australia in 2023....
Read More
Aristocrat v Commissioner of Patents – the latest update
Aristocrat v Commissioner of Patents – the latest update In the latest appeal by Aristocrat Technologies Australia Pty Limited (Aristocrat) against a decision of the Commissioner of Patents, Burley J...
Aristocrat v Commissioner of Patents – the latest update In the latest appeal by Aristocrat Technologies Australia Pty Limited (Aristocrat)...
Read More
China: Patents and invalidation challenges – navigating translation accuracy
The accurate translation of patent documents from English to Chinese is crucial to circumvent potential invalidation or infringement disputes in China. Once embroiled in legal challenges, amending translation inaccuracies...
The accurate translation of patent documents from English to Chinese is crucial to circumvent potential invalidation or infringement disputes...
Read More
China: Patent Guidelines for Examination – changes for AI, big data and software
On 21 December 2023, along with revised implementation rules for patent law, the China Intellectual Property Administration (CNIPA) issued an updated Guidelines for Patent Examination (the Guidelines). The changes...
On 21 December 2023, along with revised implementation rules for patent law, the China Intellectual Property Administration (CNIPA) issued...
Read More